Posts tagged revenue
Profound Medical in $10-million bought deal, Q2 revenue up 62%

Profound Medical (OTCQB:PRFMF; TSXV:PRN) reported second quarter revenue of $957,139, compared to nil in the year ago quarter, but up 62% from $591,517 in the first quarter of 2017.

Read More
Roth ups iRadimed to buy

Roth Capital Partners upgraded iRadimed (NASDAQ:IRMD) to “buy” from “neutral” and raised its price target to $12 from $9 after the company reported second quarter results. The stock closed at $9.80 on July 31.

Read More
Titan Pharma in debt facility with Horizon Technology

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a venture loan and security agreement with Horizon Technology Finance (NASDAQ:HRZN), which provides Titan with up to $10-million of available borrowing capacity.

Read More
Tetra Bio-Pharma names Bernard Fortier as CEO

Tetra BioPharma (OTCQB:TBPMF; CSE:TBP) appointed Bernard Fortier to the position of CEO, effective July 24. 

Read More
Canaccord ups OraSure price target to $18

Canaccord Genuity raised its price target for OraSure Technologies (NASDAQ:OSUR) to $18 from $15 after the company entered a four-year, up to $20-million agreement with the Bill & Melinda Gates Foundation, which will effectively subsidize the cost of the HIV self test.

Read More
Microbix posts 84% jump in Q1 revenue

Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier.

Read More
Mackie ups Profound Medical price target to $4.40

Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.

Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.

Read More
BioSyent signs distribution pact for two CV products

BioSyent (TSX-V:RX; OTC:BIOYF) has signed an exclusive distribution agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market.

The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. BioSyent intends to submit the dossier seeking marketing approval of the products to Health Canada in 2016.

Read More
Nobilis Health Q1 revenue climbs 35%

First quarter revenue for Nobilis Health (NYSE MKT:HLTH; TSX:NHC) rose 35% to a record $51.3-million, driven by increased case flow and a higher average revenue per case.

In the first quarter, we invested heavily in new technology and infrastructure to support our forecasted growth in 2016,” CEO, Harry Fleming, said in a statement.

Read More
Roth reinitiates coverage of NeoGenomics at buy

Roth Capital Partners has reinitiated coverage on NeoGenomics with a “buy” rating and target price of $10, following its acquisition of Clarient from GE Healthcare. The stock closed at $8.34 on Tuesday.

“We believe NeoGenomics is on the brink of demonstrating significant sales growth and operating leverage over the next several years as the two companies become fully integrated and realize likely better-than-anticipated revenue and cost synergies,” writes analyst Chris Lewis.

Read More
Incyte to acquire ARIAD’s EU operations, in-license Iclusig

Incyte (NASDAQ:INCY) has agreed to acquire ARIAD Pharmaceuticals’ (NASDAQ:ARIA) European operations. At the expected June 1 closing of the transaction, Incyte will obtain an exclusive license to develop and commercialize Iclusig in Europe and other select countries.

The agreement to divest its European operations and out-license Iclusig in Europe will enable ARIAD to focus its promotion of Iclusig on the highly valuable U.S. market, while strengthening its financial position and maintaining important optionality through a potential buy-back provision for the Iclusig license rights in the event of a change-in-control of ARIAD.

Read More
TearLab Q1 revenue climbs 25%

First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 25% to $6.8-million from $5.4-million a year ago.

A net total of 257 TearLab Osmolarity Systems were added in the first quarter of 2016, of which 167 were under the company’s new Flex program and 61 were purchased outside of the U.S.

Read More
Novadaq posts 54% jump in Q4 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported revenue of $20-million for the final quarter of 2015, up 54% from $13-million in the year earlier quarter, and up 18% from the third quarter of 2015.

Product sales increased by $9.3-million, or 95%, primarily due to an 89% increase in capital sales and a 107% increase in recurring revenue.

Read More
Novadaq Q4 revenue to jump about 54%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has released preliminary unaudited revenue for the fourth quarter of 2015 of approximately $20-million, reflecting increases of about 54% from $13-million in the 2014 fourth quarter and 18% sequentially over $17-million in the third quarter last year.

For all of 2015, the company anticipates total revenues to be approximately $63.8-million, representing total year-over-year revenue growth of about 37%.

Read More